Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25years old enrolled in a clinical study

Cancer Science

Volumn 102, Issue 4, 2011, Pages 877-882

  Konno, Ryo ^a   Tamura, Shinobu ^b   Dobbelaere, Kurt ^c   Yoshikawa, Hiroyuki ^d  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Development and Medical Affairs Division   (Japan)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AIMMUGEN; ALUMINUM HYDROXIDE; AS 04; HEPATITIS A ANTIGEN; HEPATITIS A VACCINE; IMMUNOLOGICAL ADJUVANT; UNCLASSIFIED DRUG; VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOLOGY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; IMMUNOGENICITY; JAPANESE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL; VACCINATION; VIRUS LIKE AGENT; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; PREVALENCE; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS; WOMEN'S HEALTH; YOUNG ADULT;

EID: 79952745264     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01878.x     Document Type: Article

References (44)

1. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
2. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs 2010; 70: 1079-98.
4. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24(Suppl 1): S1-15.
5. Munoz N, Bosch FX, de Sanjosé S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
6. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-32.
7. Castellsagué X, De Sanjosé S, Aguado T et al. HPV and Cervical Cancer in the World: 2007 report (Section I Continents and Regions). Vaccine 2007; 25: C1-26.
8. Wright TC Jr, Huh WK, Monk BJ et al. Age considerations when vaccinating against HPV. Gynecol Oncol 2008; 109: S40-7.
9. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008; 110: S1-10.
10. Descamps D, Hardt K, Spiessens B et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009; 5: 332-40.
11. The GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4years. Lancet 2009; 374: 1975-85.
12. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8.
13. Villa LL, Ault KA, Giuliano AR et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-83.
14. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70.
15. Ault KA, The Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-8.
16. Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
17. Olsson S-O, Paavonen J. Impact of HPV 6/11/16/18 vaccine on abnormal Pap tests and procedures. Abstract O-01.08. 25th International Papillomavirus Conference. 2010, May 8-12, 2009, Malmo Sweden.
18. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
19. Harper DM. Current prophylactic HPV vaccines and gynecologic pre-malignancies. Curr Opin Obstet Gynecol 2009; 21: 457-64.
20. Cuzick J. Long-term cervical cancer prevention strategies across the globe. Gynecol Oncol 2010; 117: S11-4.
21. Castellsagué X, De Sanjosé S, Aguado T et al. HPV and Cervical Cancer in the World: 2007 Report (Section II Countries). Vaccine 2007; 25: C27-219.
22. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in Japan. Summary Report 2010. 22 June 2010. [Cited 27 Apr 2010.] Available from URL: .
23. Japanese Ministry of Health, Labour & Welfare. Vital Statistics Japan. 21 Oct 2009. [Cited 16 Nov 2010.] Available from URL: .
24. Marugame T, Matsuda T, Kamo K et al. Cancer incidence and incidence rates in Japan in 2001 based on the data from 10 population-based cancer registries. Jpn J Clin Oncol 2007; 37: 884-91.
25. Garland S, Park SN, Ngan HY et al. The need for public education on HPV and cervical cancer prevention in Asia. Opinions of experts at the AOGIN conference. Vaccine 2008; 26: 5435-40.
26. Onuki M, Matsumoto K, Satoh T et al. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 2009; 100: 1312-6.
27. Inoue M, Sakaguchi J, Sasagawa T et al. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 2006; 16: 1007-13.
28. Konno R, Dobbelaere KO, Godeaux OO et al. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7. Int J Gynecol Cancer 2009; 19: 905-11.
29. Konno R, Tamura S, Dobbelaere K et al. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25years: interim analysis of a phase 2 double-blind, randomized, controlled trial. Int J Gynecol Cancer 2010; 20: 404-10.
30. Konno R, Tamura S, Dobbelaere K et al. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25years: final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer 2010; 20: 847-55.
31. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65.
32. Konno R, Shin HR, Kim YT et al. Human papillomavirus infection and cervical cancer prevention in Japan and Korea. Vaccine 2008; 26(Suppl 12): M30-42.
33. Miura S, Matsumoto K, Oki A et al. Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 2006; 119: 2713-5.
34. Garland SM, Cuzick J, Domingo EJ et al. Recommendations for cervical cancer prevention in Asia Pacific. Vaccine 2008; 26(Suppl 12): M89-98.
35. Dunne EF, Unger ER, Sternberg M et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-9.
36. Asato T, Maehama T, Nagai Y et al. A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 2004; 189: 1829-32.
37. Bao YP, Li N, Smith JS et al. Human papillomavirus type-distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 2008; 18: 71-9.
38. Chang Y, Brewer NT, Rinas AC et al. Evaluating the impact of human papillomavirus vaccines. Vaccine 2009; 27: 4355-62.
39. De Vuyst H, Clifford G, Li N et al. HPV infection in Europe. Eur J Cancer 2009; 45: 2632-9.
40. Nielsen A, Kjaer SK, Munk C et al. Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12, 000 younger and older Danish women. Sex Transm Dis 2008; 35: 276-82.
41. Levi F, Lucchini F, Negri E et al. Cervical cancer mortality in young women in Europe: patterns and trends. Eur J Cancer 2000; 36: 2266-71.
42. de Villiers EM, Fauquet C, Broker TR et al. Classification of papilloma-viruses. Virology 2004; 324: 17-27.
43. Wheeler CM, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26years. J Infect Dis 2009; 199: 936-44.
44. Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26years. J Infect Dis 2009; 199: 926-35.